Drug Interaction Report

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Concomitant administration with moderate or potent inhibitors of CYP450 2C9 may increase the plasma concentrations of deuruxolitinib, which is primarily metabolized via this isoenzyme. A model-informed approach predicted that coadministration with multiple doses of a potent CYP450 2C9 inhibitor with a single 12 mg dose of deuruxolitinib (1.5 times the approved 8 mg dose) would increase deuruxolitinib systemic exposure (AUC) by 200% and peak plasma concentration (Cmax) by 25%. Similarly, coadministration of deuruxolitinib (12 mg) with multiple doses of fluconazole 200 mg, a dual moderate CYP450 3A4 and CYP450 2C9 inhibitor, increased deuruxolitinib's AUC and Cmax by 140% and 21%, respectively. Additionally, individuals who are poor metabolizers of CYP450 2C9 are expected to have higher exposure of deuruxolitinib, which may increase the risk serious adverse reactions such as thrombosis. Based on drug-drug interaction modeling data, CYP450 2C9 poor metabolizers may have up to 2-fold higher concentration of deuruxolitinib, when compared to normal metabolizers. Pharmacokinetic data of deuruxolitinib for individuals who are intermediate metabolizers have not been evaluated.

MANAGEMENT: Concomitant use of deuruxolitinib with moderate or potent inhibitors of CYP450 2C9 is considered contraindicated.

Food increases the blood levels of this medication. If you are only receiving one or two doses, you may take it without regard to meals. However, if you are receiving the medication for long-term treatment, you should take it with food at the same time everyday to maintain consistent blood levels and effects. Avoid consuming grapefruit or grapefruit juice during treatment, as it may increase blood levels of the medication to undesirable levels and increase the risk of side effects, including headache, dizziness, fatigue, nausea, vomiting, cramping, diarrhea, hypokalemia (low blood potassium), fluid retention, swelling, and high blood pressure. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Consumer information for this interaction is not currently available.

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.